New results from a study in metastatic breast cancer presented today at the 31st Annual CTRC-AACR San Antonio Breast Cancer Symposium showed that the combination of Tykerb? (lapatinib ditosylate) plus letrozole, as a first line treatment regimen, provided a significant improvement in delaying disease progression when compared to treatment with Femara® (letrozole) alone.
More...